Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
New insights from Spherix Global Insights reveal strong rheumatologist anticipation for next-generation oral and multi-pathway innovations, including Sotyktu, icotrokinra, and sonelokimab. EXTON, PA, November 13, 2025 – The 2025 Market Dynamix™: Psoriatic Arthritis and Ankylosing Spondylitis/Non-Radiographic Axial Spondyloarthritis (EU5) studies from Spherix Global Insights reveal a rapidly evolving treatment landscape,
Physicians highlight early intervention, safety, and access limitations as key unmet needs—Tepezza SC anticipated to reshape the treatment paradigm in 2026 EXTON, PA, November 12, 2025 — New research from Spherix Global Insights finds that while Amgen’s Tepezza (teprotumumab) continues to anchor the treatment landscape for thyroid eye disease (TED),
Familiarity with AstraZeneca’s Saphnelo and enthusiasm for next-generation biologics signal increasing optimism, though CAR T-cell therapy divides opinion amid safety and access concerns, according to Spherix Global Insights EXTON, PA, November 6, 2025 – According to the latest Market Dynamix™: Systemic Sclerosis (US) 2025 study from Spherix Global Insights, the
Strong enthusiasm for novel modalities is tempered by neurologists’ demands for clinically meaningful endpoints and data superiority, according to Spherix Global Insights. Exton, PA., November 03, 2025 – Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S. neurologists across five key
Exton, PA., October 31, 2025 — Spherix Global Insights has announced the launch of its latest Market Dynamix™ service, PD-1 Inhibition in Solid Tumors (US) 2025, providing an in-depth analysis and advisory services for the evolving immuno-oncology landscape as the next wave of PD-1 biosimilars and subcutaneous (SC) formulations rapidly
New analysis from Spherix Global Insights reveals 90% retention on first-line gMG biologics, with Alexion’s Ultomiris® and argenx’s Vyvgart® (IV) leading prescribing. Exton, PA., October 29, 2025 – Spherix Global Insights has released its latest Patient Chart Dynamix™: Treatment Patterns in Generalized Myasthenia Gravis (US), delivering a comprehensive view of real-world
Exton, PA., October 28, 2025 – The membranous nephropathy (MN) treatment paradigm is on the brink of transformation, with physicians signaling strong interest in novel mechanisms of action and shifting away from legacy regimens, according to Spherix Global Insights’ recently published Market Dynamix™: Membranous Nephropathy (US) 2025 service. Nephrologists describe MN as one
Despite two recent FDA approvals, two-thirds of physicians report high unmet need in CSU, highlighting potential for clinical advancement, according to Spherix Global Insights. EXTON, PA, October 24, 2025 – Chronic spontaneous urticaria (CSU), marked by unpredictable and often debilitating flare patterns, continues to impose a significant burden on patients
New Spherix Global Insights data reveal growing physician demand for therapies that reduce treatment burden and elevate patient experience. EXTON, PA – October 22, 2025 — Hematologists across the United States are redefining what “success” looks like in hemophilia treatment, according to the latest findings from Market Dynamix™: Hemophilia (US)
With multiple late-stage assets advancing, manufacturers have a near-term opportunity to drive much-needed disease education and shape therapeutic direction. EXTON, PA, October 16, 2025 – Sjögren’s Disease (SjD) continues to present significant diagnostic and therapeutic challenges within rheumatology, according to Spherix Global Insights’ Market Dynamix™: Sjögren’s Disease (US) 2025 report.
Inaugural coverage will include multiple myeloma, myelodysplastic syndrome and B-cell malignancies (large B-cell lymphoma and chronic lymphocytic leukemia). EXTON, PA., October 15, 2025 – Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, today announced the expansion of
New payer research highlights tightening formularies, shifting contracting models, and rising cost-containment pressures heading into 2026. EXTON, PA, October 14, 2025 – Spherix Global Insights announces the release of Special Topix™: Payer Management Strategies, a comprehensive new analysis examining how U.S. health plans and pharmacy benefit managers (PBMs) are redefining
Physician sentiment captured in Spherix Global Insights’ research highlights high expectations for dual TYK2/JAK1 inhibition, with continued unmet needs across the broader IIM spectrum. EXTON, PA, October 10, 2025 – Rheumatologists are eagerly anticipating the potential approval of brepocitinib, Priovant Therapeutics’ dual TYK2/JAK1 inhibitor, as a near-term advance for dermatomyositis
New research reveals cautious optimism as physicians weigh transformative potential against safety, access, and the enduring role of biologics and advanced systemics across rheumatic conditions. EXTON, PA, October 6, 2025 – Cell therapy may represent a new frontier in the treatment of autoimmune diseases, with the majority of US rheumatologists
New data from Spherix Global Insights uncover how hematologists are defining the “right patient” for gene therapy, balancing promise with practical barriers in sickle cell disease, thalassemia, and hemophilia. October 2, 2025 [Exton, PA] – According to the newly released Special Topix™: Adoption and Impact of Gene Therapy in Hematology,
The white paper illustrates how recent lupus launches, including Lupkynis (Aurinia), Benlysta (GSK), and Saphnelo (AstraZeneca), showcase the critical role of strategic differentiation and targeted education in driving future uptake. Exton, PA, October 2, 2025 – Spherix Global Insights has released a new white paper, Navigating the Evolving SLE/Lupus Nephritis
Media
04.08.2024
Pfizer’s Velsipity poised to outpace BMS’ Zeposia in ulcerative colitis market, but must head off further competition: analysts
04.08.2024
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
04.05.2024
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of…
03.22.2024
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for…
